MANCHESTER KEITH S

Director Keith Manchester sold 1,225,784 shares of ROIV for $32,658,518.16 across 5 transactions (Feb 11-13) at blended $26.64, reducing stake by 7.5%.

Keith Manchester, a Director at Roivant Sciences, executed 5 separate sales totaling 1,225,784 shares for $32,658,518.16 over three trading days (February 11-13, 2026) at prices averaging $26.64, reducing his post-transaction holdings to 15,127,329 shares. The sale occurred near the stock's 52-week high of $27.67 and follows strong recent momentum: the stock is up 11.1% over 30 days and up 30.4% over 90 days. However, context suggests structural headwinds: the company reported annual revenue of $1,999,000.00 in its latest quarter, annual revenue declined 76.7% year-over-year, and full-year net income was negative ($-265,891,000.00). Across Manchester's open-market trading history, his prior 15 sells show an average 90-day return of +1.0% with a 0.00% well-timed rate, indicating his recent sells have been poorly timed relative to post-sale price movements. This large, multi-day disposition at elevated valuation warrants attention given the company's deteriorating operational scale and Manchester's historical difficulty timing exits.

Director Keith Manchester sold 1,694,614 shares at blended avg $23.05 for $39.1M, reducing stake by 9.4%

Director Keith S. Manchester executed 5 separate sales totaling 1,694,614 shares for $39,065,213.44 on 2025-12-16 and 2025-12-17, at prices ranging from $22.93 to $23.17. This represents a 9.4% reduction in his holdings to 16,353,113 shares post-transaction. The shares were sold at prices near the 52-week high of $22.94, with the current price now at $21.79, placing the transaction within 5.0% of the 52-week peak. Notably, Manchester's cross-ticker track record shows a 0.00% well-timed rate on prior sells (10 prior sales averaging -17.8% 30-day return), and at ROIV specifically, his only measurable prior sale on 2025-09-25 returned +2.0% at the 90-day mark—meaning the stock rose after his sell, not fell. Meanwhile, ROIV's fundamentals show severe deterioration: annual revenue declined 76.7% to $1,571,000.00 in the latest quarter, net income was $-113,519,000.00, and the company remains deeply unprofitable on a full-year basis.

Director Keith S Manchester sells 1,300,000 shares (6.7% of holding) for $26,304,500.00 at ROIV; retains 18.05M shares post-sale

Director Keith S Manchester executed 4 separate sales totaling 1,300,000 shares for $26,304,500.00 on 2025-11-19, reducing his holdings by 6.7% from 19,347,727 to 18,047,727 shares at a blended average price of $20.23, near the current price of $20.22. Contextually, the stock has appreciated 12.6% over the prior 30 days and 69.6% over 90 days, suggesting the transaction occurred during an upswing. At the same-ticker level, his 5 prior sales at ROIV produced 0 of 5 well-timed outcomes at the 90-day mark, indicating no demonstrated pattern of selling ahead of declines. The company is unprofitable (net income of $-113,519,000.00 for its most recent full year) with severely contracted revenue (down 76.7% annually), and the latest quarterly revenue of $1,571,000.00 signals material operational stress. The director's continued substantial holdings (18.05M shares) indicate meaningful retained exposure despite the sale.

Director Keith Manchester sold 503,000 shares (28.3% of holdings) across two days for $5,866,308.20 at blended average $11.66

Keith Manchester, a director at Roivant Sciences, executed two separate sales totaling 503,000 shares (503.0K shares) for $5,866,308.20 on 2024-09-24 and 2024-09-25, reducing his holding by 28.3% from 1,780,178 to 1,277,178 shares. The sales occurred at a blended average price of $11.66, modestly above the current price of $11.57 but still 12.3% below the 52-week high of $13.19. Manchester's cross-ticker track record shows an average 90-day return of +0.3% following prior sells (well-timed rate 0.00%), indicating his past sales have not consistently preceded declines; his prior same-ticker trades at ROIV in September 2023 similarly realized a 90-day return of +0.3%, suggesting a pattern of sales followed by stock appreciation. The magnitude of this liquidation—reducing exposure by more than one quarter in two trading days—stands against the backdrop of the company's robust fundamentals (P/E of 1.81, revenue growth of +103.6% year-over-year, and market cap of $8.6B), leaving the reduction itself as the primary observable signal without clear timing advantage relative to his historical pattern.